What is HC Wainwright's Estimate for Ocugen FY2028 Earnings?

Key Points

• HC Wainwright lowered its FY2028 EPS estimate for Ocugen to a loss of $0.43 per share, compared with its prior forecast of a $0.41 loss and the consensus estimate of a $0.25 loss.
• Analyst sentiment remains mixed but leans positive: Ocugen has a consensus “Moderate Buy” rating and a $9.50 target price, despite some downgrades and lowered price targets.
• Ocugen’s shares opened at $1.02, near their 52-week low, after the company reported a quarterly loss of $0.07 per share that missed expectations. Institutional ownership stands at 10.27%, while CEO Shankar Musunuri sold shares under a pre-arranged Rule 10b5-1 plan.

Ocugen, Inc. (NASDAQ:OCGN - Free Report) - Equities research analysts at HC Wainwright decreased their FY2028 earnings estimates for shares of Ocugen in a research note issued on Thursday, September 10th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($0.43) per share for the year, down from their prior estimate of ($0.41). The consensus estimate for Ocugen's current full-year earnings is ($0.25) per share.

Other analysts have also recently issued research reports about the company. Canaccord Genuity Group dropped their price objective on Ocugen from $12.00 to $11.00 and set a "buy" rating for the company in a research report on Wednesday, May 27th. Weiss Ratings upgraded shares of Ocugen from a "sell (e+)" rating to a "sell (d-)" rating in a report on Tuesday, August 11th. Finally, Wall Street Zen downgraded shares of Ocugen from a "hold" rating to a "sell" rating in a report on Saturday, August 8th. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $9.50.

Ocugen Stock Performance

NASDAQ OCGN opened at $1.02 on Monday. The company has a quick ratio of 0.80, a current ratio of 0.80 and a debt-to-equity ratio of 4.17. Ocugen has a fifty-two week low of $1.01 and a fifty-two week high of $2.73. The business has a fifty day moving average of $1.33 and a 200-day moving average of $1.53. The stock has a market cap of $345.89 million, a price-to-earnings ratio of -3.92 and a beta of 2.20.

Ocugen (NASDAQ:OCGN - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.02). The business had revenue of $1.49 million for the quarter, compared to analysts' expectations of $0.89 million.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in shares of Ocugen in the second quarter worth approximately $41,314,000. Vanguard Group Inc. increased its position in Ocugen by 3.1% during the third quarter. Vanguard Group Inc. now owns 15,223,585 shares of the company's stock worth $24,814,000 after purchasing an additional 450,904 shares during the last quarter. Millennium Management LLC raised its stake in Ocugen by 29.7% during the fourth quarter. Millennium Management LLC now owns 5,396,417 shares of the company's stock worth $7,285,000 after purchasing an additional 1,234,268 shares during the period. UBS Group AG raised its stake in Ocugen by 373.2% during the fourth quarter. UBS Group AG now owns 4,849,353 shares of the company's stock worth $6,547,000 after purchasing an additional 3,824,474 shares during the period. Finally, State Street Corp boosted its holdings in shares of Ocugen by 193.6% in the 4th quarter. State Street Corp now owns 3,978,738 shares of the company's stock valued at $5,371,000 after purchasing an additional 2,623,361 shares during the last quarter. Institutional investors and hedge funds own 10.27% of the company's stock.

Insider Activity

In other news, CEO Shankar Musunuri sold 57,264 shares of Ocugen stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $1.12, for a total value of $64,135.68. Following the completion of the sale, the chief executive officer owned 1,088,035 shares of the company's stock, valued at $1,218,599.20. The trade was a 5.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 3.95% of the stock is owned by company insiders.

Ocugen News Summary

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: An analyst maintains a bullish view, assigning Ocugen a Buy rating based on progress in its OCU400, OCU410ST and OCU410 gene-therapy programs. Upcoming pivotal-trial catalysts, including OCU410ST Stargardt disease data, could provide a significant boost if results are favorable. Ocugen: Q3 Data Catalyst In Stargardt Disease Feels Critical
• Neutral Sentiment: Ocugen’s FDA-cleared Phase 3 pathway for OCU410 and planned 2027 Phase 3 data represent potentially important milestones, but the programs still carry substantial clinical, commercialization and execution risk. Another analysis retained a Hold rating while acknowledging the OCU410ST advancement and upcoming catalysts. Ocugen: My Hold Rating Continued On OCU410ST Advancement And Upcoming Catalysts
• Negative Sentiment: CEO Shankar Musunuri sold a combined 525,991 shares at an average price of $1.12, reducing his reported ownership in two transactions. The sales were executed under a pre-arranged Rule 10b5-1 plan, which lessens the signal that they reflect a change in management’s outlook, but the sizable transactions may nevertheless weigh on sentiment. SEC insider-trading filing
• Negative Sentiment: HC Wainwright lowered its EPS forecasts for both FY2029 and FY2030, cutting the estimates to $0.06 from $0.14 and to $0.98 from $1.08, respectively. The revisions suggest a less favorable earnings outlook despite expectations that Ocugen remains unprofitable in the current fiscal year.
• Negative Sentiment: Investors are still processing disappointing interim clinical-trial data, which has limited enthusiasm for the pipeline and added risk ahead of future readouts. The stock is trading near its one-year low and below its 50-day and 200-day moving averages.

Ocugen Company Profile

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.